ARMOR (Analyzing Renal Mechanisms of Creatinine Excretion in Patients On tesaglitazaR)
Status:
Terminated
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
This is a prospective 24-week, randomized, parallel-group, multi-center, active-controlled
(pioglitazone 45 mg) open-label study designed to assess the effects of tesaglitazar 2 mg per
day on components of renal excretion of creatinine in type 2 diabetics. The study comprises a
2-week enrollment period, followed by a 24-week double blind treatment period and an 8-week
follow-up period